Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCL-PG04 step-wise obinutuzumab + vemurafenib + cobimetinib in hairy cell leukemia
2024-520121-36-00Phase 2Authorised
- Sponsor
- University of Perugia
- Start
- Jan 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab, vemurafenib and cobimetinib in hairy cell leukemia (HCL), sponsored by University of Perugia. Primary endpoints: Response rate (per-protocol) and Response rate (intention-to-treat). Planned start Jan 2025; status: authorised.
02
Drugs
obinutuzumabvemurafenibcobimetinib
03
Conditions
hairy cell leukemia (HCL)
Beyond the preview
Go deeper on 2024-520121-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520121-36-00.